Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=funder" }, "data": [ { "type": "Grant", "id": "12020", "attributes": { "award_id": "5R21AG073974-03", "title": "The effect of Social Isolation on Lexical Retrieval in Elderly Adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21737, "first_name": "Elizabeth Anne", "last_name": "Necka", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2024-04-30", "award_amount": 195000, "principal_investigator": { "id": 26424, "first_name": "Loraine K.", "last_name": "Obler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27906, "first_name": "Amy Victoria", "last_name": "Vogel-Eyny", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1565, "ror": "https://ror.org/00g2xk477", "name": "Hunter College", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Coming up with the word we want to say (lexical retrieval) is a worrying concern among older adults. Those with dementia, naturally, experience difficulty on lexical-retrieval tasks, but typical older adults do as well. They may struggle with people’s names, but also with words for objects. Moreover, while the problems arise primarily for low-frequency words, they sometimes arise even when the word is quite familiar. Such problems with lexical retrieval appear to be compounded by the lack of speaking opportunities resulting from the social isolation that often accompanies aging in 21st century North America, and, we propose, particularly so by the extremes which have accompanied COVID-19 for many in 2020. In this project, we use a refined task to induce tip-of-the-tongue (TOT) experiences and predict that performance on that task will correlate with the degree of social isolation which our participants have endured. Moreover, increases in such communication lapses can lead to frustration, breakdowns in conversation, and, paradoxically, a desire to withdraw from social interactions in order to avoid the perception of communicative incompetence. Although substantial advances have been made in our understanding of social isolation and its influence on cognition in aging, the scope of what can be determined from measures of cognitive performance alone is limited. Most crucially, we do not yet know the effects of reduction in communication due to social isolation on word retrieval. In Study 1, we propose to retest the 53 healthy participants tested for a different project in the period leading up to COVID-19 on TOT stimuli, using items they did not see in the earlier test. A self-report of changes in social contact and communicative exchanges due to COVID-19 will allow us to gauge whether a change in social connection impacts word-finding ability. We hypothesize that poorer word-finding at the second testing will correlate positively with the degree of social isolation and negatively with the extent of social communication. In Study 2 we will conduct a larger, retrospective study of social isolation and opportunities for communicative exchanges on word-finding difficulties. We will utilize the measures from Study 1 and extend them to a broader, representative cohort of healthy older adults. We hypothesize that participants involved in social activities that require expressive language will perform better on our lexical retrieval measure, and that opportunities for communicative exchange will be negatively correlated with social isolation levels. Our findings will have a significant impact on public health because they will provide measures of how social isolation can affect communication and, for future efforts, make it possible to improve the language abilities of both healthy seniors and those with dementia.", "keywords": [ "Address", "Adult", "Affect", "Aging", "Alzheimer&apos", "s Disease", "Aphasia", "Buffers", "COVID-19", "Cognition", "Cognitive", "Cognitive aging", "Communication", "Dementia", "Distress", "Elderly", "Evaluation", "Family", "Frequencies", "Friends", "Frustration", "Future", "Health", "Impairment", "Interruption", "Investigation", "Language", "Lead", "Linguistics", "Longevity", "Measures", "Mental Depression", "Modification", "Names", "Neurodegenerative Disorders", "North America", "Outcome", "Participant", "Patient Self-Report", "Perception", "Performance", "Persons", "Population", "Positioning Attribute", "Primary Progressive Aphasia", "Production", "Public Health", "Quality of life", "Questionnaires", "Radio", "Reporting", "Research", "Retrieval", "Retrospective Studies", "Retrospective cohort", "Risk", "Role", "SARS-CoV-2 transmission", "Social Distance", "Social Interaction", "Social Network", "Social isolation", "Specific qualifier value", "Stimulus", "Testing", "Tongue", "Withdrawal", "Work", "age related", "clinically significant", "cognitive performance", "cognitive process", "cohort", "executive function", "experience", "experimental study", "follow-up", "healthy aging", "improved", "lexical retrieval", "member", "mild cognitive impairment", "nervous system disorder", "novel", "social", "social communication", "social contact", "social engagement", "social interventions", "social situation", "therapeutic target", "tongue apex", "viral transmission", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "12021", "attributes": { "award_id": "5P20GM109035-07", "title": "Surfaceome CRISPR screening for SARS-CoV-2 virulent proteins", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 6164, "first_name": "LAKSHMI KUMAR", "last_name": "Matukumalli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-01", "end_date": "2026-07-31", "award_amount": 198702, "principal_investigator": { "id": 27782, "first_name": "Sanghyun", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 222, "ror": "https://ror.org/05gq02987", "name": "Brown University", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of action for the majority of existing therapeutic antibodies, indicating the importance of RBD and its binding to the cellular receptor for controlling SARS-CoV-2. It is unclear whether there are any intrinsic cellular proteins that inhibit viral entry of SARS-CoV-2. Our new preliminary data reveal that cellular entry of SARS-CoV-2 is inhibited by a novel inhibitory cellular protein, Leucin-rich repeat containing 15 (LRRC15). We generated a focused CRISPR activation (CRISPRa) library, named surfaceome, that covers all ~6000 known/predicted surface proteins on the cellular plasma membrane. The surfaceome CRISPRa screening was performed by staining cells with a recombinant spike protein to identify SARS-CoV-2 binding factors. Strikingly, LRRC15 inhibits spike-mediated viral entry not only in the same cells, but also in neighboring cells in trans. Expression of LRRC15 in ACE2+ cells blocked spike-mediated viral entry in ACE2+LRRC15- cells, providing a unique concept of viral entry inhibition by an inhibitory factor. This result suggests a protective role of LRRC15 in a physiological context. Our central hypothesis is that human LRRC15 acts as an inhibitory entry factor for SARS-CoV-2, acting in trans as a decoy receptor expressed in non-susceptible pathological fibroblasts in the lung. This proposal will explore the mechanism by which LRRC15 inhibits entry of SARS-CoV-2 in trans through three subaims of Aim 1. We will leverage the screening platform to identify cellular receptors for secreted virulence proteins of SARS-CoV-2, Orf3a, Orf7a, and Orf8. Importantly, the same screening platform is validated to be a efficient platform for secreted virulent proteins. In a separate screening for norovirus secreted virulence protein (NS1), the surfaceome screening successfully identified Syndecan-4 as a putative cellular receptor for norovirus NS1 (Li et al., In preparation). In the Aim 2, we will perform a surfaceome screening for Orf3a, Orf7a, and Orf8 and will discover putative cellular receptors for the secreted virulence proteins.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12022", "attributes": { "award_id": "5R25GM142091-02", "title": "From High School to Health Care: Lab and Data Science Pathways for Success", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 9054, "first_name": "LAWRENCE A.", "last_name": "BECK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-05", "end_date": "2027-06-30", "award_amount": 262549, "principal_investigator": { "id": 25654, "first_name": "Jacen Shannon", "last_name": "Moore", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 847, "ror": "", "name": "UNIVERSITY OF TENNESSEE HEALTH SCI CTR", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The CoVID-19 pandemic amplified the stress of existing critical shortages of allied health professionals, especially in rural communities and underserved populations. Careers including clinical laboratory sciences (CLS) and public health information technology (PHIT) are less well promoted as other health professions in K-12 schools, increasing the struggle for professional programs to recruit undergraduate students. Critical needs exist for novel educational programs and training methods that promote and increase interest amongst high students about CLS and PHIT fields. The High School 2 Health Care (HS2HC) program is comprised of a summer program and a dual enrollment course that educates high school students and their teachers about careers in CLS and PHIT, while guiding them in developing hands-on skills that give them the opportunity to experience what these careers would entail. HS2HC aligns with the NIH Research Education Program goal of increasing the number of qualified, trained health professionals to meet the nation’s needs. Our program targets rural communities in West Tennessee where professional health care shortages have been exceptionally damaging and seeks to enhance opportunities in CLS and PHIT for underserved student populations. We will use novel outcomes-based educational approaches that apply project-based learning strategies to real-world social determinants of health scenarios and work-based simulation strategies with real clinical data and samples. A teacher professional development program focused on integration of NGSS and CLS and PHIT content, along with career awareness will also be implemented. A quasi-experimental mixed methods design will be used to assess awareness and knowledge and skills development in CLS and PHIT focus groups, quantitative content analysis from a dual enrollment course and a summer program, and teacher and student interviews will be used to assess effectiveness of the outcomes-based curricular design approach we use to teach interdisciplinary PHIT and CLS content, understand how rural high school students acquire knowledge regarding PHIT and CLS professions using our learning approach, and whether our approach increases student interest and the number of students choosing Career and Technical Education (CTE) and undergraduate pathways in these careers. Our unique population compositions in Lauderdale and McNairy Counties in West Tennessee will provide insight into the impact of cultural and social differences in learning acquisition for CLS and PHIT concepts, thereby allowing us to uniquely tailor our experiences to different community and cultural settings. Through high school and community partnerships, online, and mobile resources we will disseminate educational curricula, materials, and research outcomes to enhance community health-based literacy. We will encourage the addition of our program into the NGSS and CTE standards for Tennessee by communication with educators and policy makers.", "keywords": [ "Address", "Ally", "Area", "Attention", "Award", "Awareness", "Bachelor&apos", "s Degree", "COVID-19 pandemic", "Clinical", "Clinical Data", "Cognitive", "Communication", "Communities", "Community Health", "Continuing Education", "County", "Data", "Data Science", "Development", "Dual Enrollment", "Education", "Educational Curriculum", "Educational Materials", "Educational Status", "Educational process of instructing", "Ethnic Origin", "Exposure to", "Focus Groups", "Goals", "Health", "Health Occupations", "Health Professional", "Health Sciences", "Healthcare", "High School Faculty", "High School Student", "Human Resources", "Information Technology", "Interview", "Knowledge", "Knowledge acquisition", "Laboratories", "Laboratory Research", "Learning", "Management Information Systems", "Mentored Clinical Scientist Development Program", "Methods", "Next Generation Science Standards", "Operating System", "Outcome", "Outcomes Research", "Pathway interactions", "Patients", "Policy Maker", "Population", "Process", "Program Development", "Public Health", "Qualifying", "Quasi-experiment", "Research", "Research Activity", "Research Methodology", "Resources", "Rural", "Rural Community", "Rural Health", "Sampling", "Schools", "Science", "Side", "Stress", "Students", "Teacher Professional Development", "Tennessee", "Training", "Training and Education", "Underrepresented Students", "Underserved Population", "United States National Institutes of Health", "Universities", "Vocational Education", "Work", "World Health", "academic standard", "career", "career awareness", "career development", "clinical development", "cognitive process", "college", "community partnership", "design", "education research", "effectiveness evaluation", "effectiveness outcome", "experience", "health care settings", "health information technology", "health training", "high school", "improved", "insight", "interdisciplinary approach", "interest", "learning strategy", "literacy", "novel", "outreach", "profession allied to medicine", "programs", "project-based learning", "recruit", "research faculty", "response", "role model", "rural area", "rural counties", "rural underserved", "science education", "science teacher", "simulation", "skill acquisition", "skills", "skills training", "social", "social health determinants", "success", "summer program", "teacher", "tool", "undergraduate student", "underserve" ], "approved": true } }, { "type": "Grant", "id": "12023", "attributes": { "award_id": "5UL1TR001873-08", "title": "Clinical and Translational Science Award", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21618, "first_name": "Audie A", "last_name": "Atienza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-01", "end_date": "2026-05-31", "award_amount": 10299800, "principal_investigator": { "id": 27907, "first_name": "Muredach P", "last_name": "Reilly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Contact PD/PI: Reilly, Muredach P OVERALL: PROJECT SUMMARY/ABSTRACT Our mission is to improve the health of our patients and communities both locally and nationally through innovations in clinical and translational research. Our strategic vision is to catalyze all phases of clinical and translational science (T0-T4), synergize with our partners and stakeholders, and integrate activities within our hub and across the national Clinical and Translational Science Award (CTSA) Program. To achieve this vision, we will build on our strong established track-record (e.g., in precision medicine), our plans to tackle important public-health challenges (e.g., COVID-19 pandemic, the opioid crisis) and to address critical barriers (e.g., innovation in use of electronic health records for research, clinical trial designs) as we embrace the CTSA Program priorities designated in PAR-18-940. Our vision is to transform the health and wellbeing of our communities in New York City, the nation and the world. To achieve this, we deploy our programs and resources to develop, demonstrate and disseminate innovations in clinical and translational science across the full translational spectrum. As a comprehensive CTSA, we offer a broad array of support for trainees, scholars and investigators across our entire hub which includes Columbia University, the Columbia University Irving Medical Center, the New York Psychiatric Institute, and New York Presbyterian Hospital. At the same time, we move flexibly and deeply to address critical scientific or institutional opportunities as well as major public health needs and gaps. We achieve success by approaching our goals at multiple levels: a) Ongoing strategic planning including an annual retreat to review operations and identify gaps, needs and opportunities; b) Monthly cross- cutting “Theme” meetings to enable collaborative problem-solving in addressing gaps and opportunities; c) An innovative Evaluation and Continuous Improvement strategy using participatory management to integrate evaluation into program planning and execution; and d) A highly successful, innovative interdisciplinary training and workforce development program built on a foundation of team science. Central to our efforts to improve health and wellbeing at personal, community and national levels is our emphasis on strategic collaboration and dissemination. Thus, we seek to continuously create and refine innovations for an integrated research- and user- friendly translational research environment at our hub by: Harnessing partnerships across our entire hub; Transforming collaborations with our local communities, the campus health system and across New York State; And by accelerating bidirectional dissemination of innovative practices and learnings through collaborations with the CTSA Program network and beyond. Project Summary/Abstract Page 221 Contact PD/PI: Reilly, Muredach P Narrative The Clinical and Translational Science Award (CTSA) allows Columbia University to support novel programs whose goal is to speed the transition from scientific discoveries made in the laboratory toward new therapies. Building on our strong established track-record, we will tackle important challenges and critical barriers to research. We will facilitate the training of scholars from diverse backgrounds underrepresented in translational science who are knowledgeable about and available to focus on translational science later in their careers.", "keywords": [ "Acceleration", "Address", "COVID-19 pandemic", "Clinical Research", "Clinical Sciences", "Clinical Trials Design", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Dental", "Education", "Electronic Health Record", "Environment", "Evaluation", "Evolution", "Faculty", "Foundations", "Friends", "Goals", "Health", "Health Benefit", "Health system", "Healthcare", "Hospitals", "Infrastructure", "Institution", "Interdisciplinary Study", "Laboratories", "Lead", "Leadership", "Learning", "Medical center", "Medicine", "Methods", "Mission", "Modeling", "New York", "New York City", "Patients", "Personal Satisfaction", "Phase", "Physicians", "Presbyterian Church", "Problem Solving", "Process", "Program Development", "Public Health", "Public Health Schools", "Recording of previous events", "Research", "Research Methodology", "Research Personnel", "Resources", "School Nursing", "Schools", "Science", "Speed", "Strategic Planning", "Strategic vision", "Surgeon", "Time", "Training", "Translational Research", "Universities", "Vision", "Workforce Development", "career", "college", "dissemination science", "experience", "flexibility", "implementation science", "improved", "innovation", "meetings", "member", "novel", "novel therapeutics", "operation", "opioid epidemic", "precision medicine", "programs", "success", "synergism", "translational pipeline", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "12024", "attributes": { "award_id": "5R21AI171061-02", "title": "mRNA encoding of immune receptor-targeting antibodies for the augmentation of vaccine-elicited cellular immunity.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 12151, "first_name": "AARON MICHAEL", "last_name": "Joffe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-08", "end_date": "2024-06-30", "award_amount": 194375, "principal_investigator": { "id": 25542, "first_name": "Ross M", "last_name": "Kedl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary. Clinically relevant cellular responses to either experimental or FDA approved vaccine adjuvant formulations have been difficult to generate and/or detect. We have long been investigating a combined adjuvant formulation (composed of a TLR agonist and an agonistic antiCD40 antibody) which generates cellular immunity on par with that observed to infectious challenge. The complexity of this three-part vaccine (antigen plus TLR/CD40) is limiting to its clinical application. However, the success of lipid nanoparticle (LNP) encapsulated mRNA vaccines for Covid provides a possible avenue by which our combination adjuvant might be successfully translated into clinical use against chronic infectious diseases and cancer. Our preliminary results show that we can agonize the CD40 pathway, sufficient to augment CD8 T cell responses, by mRNA- mediated delivery of the heavy and light chains of the agonistic anti-CD40 antibody FGK45. The success of this method for targeting CD40 strongly favors the hypothesis that antibodies specific for other immunotherapeutic molecular targets (eg. CTLA4, PD1) might also be successfully delivered via the mRNA vaccination strategy. Completion of this project would not only identify a new and powerful means by which the established potency of our combined adjuvant might be leveraged for clinical application, they open an entirely new paradigm in the use of mRNA vaccination for targeting immunologically relevant molecules for the purposes oncologic checkpoint therapy and beyond.", "keywords": [ "Adjuvant", "Adjuvant Study", "Admission activity", "Agonist", "Anti-CD40", "Antibodies", "Antibody Formation", "Antibody Response", "Antigens", "Area", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19", "COVID-19 vaccine", "CTLA4 gene", "Cells", "Cellular Immunity", "Chronic", "Clinical", "Communicable Diseases", "Data", "Development", "Encapsulated", "Engineering", "FDA approved", "Formulation", "Frequencies", "Genes", "Goals", "Humoral Immunities", "Immune", "Immune Targeting", "Immune response", "Immune system", "Immunity", "Immunization", "Immunologic Receptors", "Immunologics", "Immunotherapeutic agent", "Individual", "Infection", "Interferon Type I", "Intervention", "Intravenous infusion procedures", "Life", "Light", "Lipids", "Malignant Neoplasms", "Measures", "Mediating", "Memory", "Messenger RNA", "Methods", "Modeling", "Molecular Target", "Monoclonal Antibodies", "Mus", "Nature", "Oncology", "Pathway interactions", "Patients", "Phenotype", "Problem Solving", "Qualitative Evaluations", "RNA vaccination", "RNA vaccine", "Research Project Grants", "SARS-CoV-2 immunity", "Signal Pathway", "Signal Transduction", "Source", "Stimulus", "T cell response", "T memory cell", "T-Lymphocyte", "TNFRSF5 gene", "Technology", "Testing", "Therapeutic", "Therapeutic Intervention", "Translating", "Treatment Efficacy", "Treatment Protocols", "Tumor Promotion", "Vaccination", "Vaccine Adjuvant", "Vaccines", "Validation", "Variant", "Work", "anti-CTLA4", "anti-PD-1", "checkpoint therapy", "chronic infection", "clinical application", "clinical implementation", "clinically relevant", "cost", "experimental study", "immune checkpoint blockade", "in vivo", "lipid nanoparticle", "mRNA delivery", "manufacture", "nanoparticle", "nonhuman primate", "pandemic disease", "particle", "programmed cell death protein 1", "protein purification", "research clinical testing", "response", "single-cell RNA sequencing", "stem cells", "success", "therapeutic target", "tumor", "vaccination strategy", "vaccine delivery", "vaccine platform", "vaccine-induced immunity", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "12025", "attributes": { "award_id": "5R21EB031401-02", "title": "Drop-of-blood technology for diagnosis and therapeutic drug monitoring in patients with infectious disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-15", "end_date": "2025-04-30", "award_amount": 190000, "principal_investigator": { "id": 25543, "first_name": "Damir B", "last_name": "Khismatullin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic took lives of more than 2.5 million people globally including more than 500 thousand in the United States in one year. Many deaths occurred after rapid health deterioration, shortly after symptoms of the disease were manifested. Clinical evidence collected from patients with severe disease indicates that this deterioration occurred because of the cytokine storm and resulting activation of the coagulation system, leading to uncontrolled thrombotic events in pulmonary microvasculature and throughout the body. Similar to COVID-19, severe complications of other infectious diseases are known to be associated with coagulation abnormalities causing disseminated intravascular coagulation, venous thromboembolism, arterial thrombosis, or ischemic stroke. High levels of D-dimer, the test for hyperactive coagulation system, were found to be correlated with high mortality in patients with infectious disease including COVID-19. Many of these patients could be saved if they were properly and timely treated based on infectious disease risk assessment. However, tests that effectively predict the severity of infectious diseases are not available yet. The objective of this proposal is to develop a drop-of-blood test for rapid point-of-care assessment of infectious disease severity, based on integrated quasi-static acoustic tweezing thromboelastometry (i-QATT). In this unique approach, comprehensive coagulation analysis is done without inducing blood sample contact with artificial surfaces and by using a single drop of blood, which volume (4-6 microliters) is nearly 100 times less the minimal sample volume currently required for coagulation tests. For rapid assessment of infectious disease risk inside a hospital or under outpatient settings, we propose to use this method on venous blood samples or finger prick capillary blood samples. We hypothesize that 1) i-QATT capillary blood analysis can detect coagulation abnormalities, 2) severe complications from infectious diseases develop due to cytokine storm-induced activation of the coagulation system, and 3) severity of infectious diseases can be assessed from blood coagulation analysis. The technology development for infectious disease severity assessment and testing the above hypotheses will be achieved via the following specific aims: 1) establish and standardize the acoustic tweezing technology for coagulation measurements of capillary blood, 2) assess changes in the coagulation system induced by cytokine storm via drop-of-blood measurements, and 3) test the feasibility of drop-of-blood acoustic tweezing technology for infectious disease severity assessment.", "keywords": [ "Acoustics", "Activated Partial Thromboplastin Time measurement", "Acute Respiratory Distress Syndrome", "Anticoagulants", "Blood", "Blood Tests", "Blood capillaries", "Blood coagulation", "Blood specimen", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 severity", "COVID-19 vaccine", "Cessation of life", "Clinic", "Clinical", "Clinical Data", "Coagulation Factor Deficiency", "Coagulation Process", "Communicable Diseases", "Critical Illness", "Data", "Deterioration", "Development", "Devices", "Diagnosis", "Disease", "Disseminated Intravascular Coagulation", "Drops", "Drug Monitoring", "Emerging Communicable Diseases", "Endothelial Cells", "Event", "Exposure to", "Factor XIII", "Fibrin fragment D", "Fibrinogen", "Fibrinolysis", "Fibrinolytic Agents", "Fingers", "Flow Cytometry", "Gene Expression Profiling", "Goals", "Health", "Hemorrhage", "Heparin", "Home", "Hospitals", "Human", "Hyperactivity", "Immune system", "Inflammatory", "Influenza", "Inpatients", "Ischemic Stroke", "Life", "Link", "Lung", "Measurement", "Measures", "Methods", "Modification", "Monitor", "Operating Rooms", "Outcome", "Outpatients", "Patients", "Persons", "Plasma", "Pneumonia", "Protocols documentation", "RNA", "Recording of previous events", "Reference Values", "Research", "Respiratory Tract Infections", "Risk Assessment", "Sampling", "Sepsis", "Severities", "Severity of illness", "Standardization", "Surface", "Symptoms", "System", "Techniques", "Technology", "Testing", "Therapeutic", "Thrombolytic Therapy", "Thrombosis", "United States", "Vascular Endothelial Cell", "Venipunctures", "Venous", "Venous blood sampling", "cytokine", "cytokine release syndrome", "disease diagnosis", "disorder risk", "experience", "experimental study", "feasibility testing", "healthy volunteer", "mortality", "multiplex assay", "outpatient facility", "pandemic disease", "platelet function", "point of care", "rapid test", "response", "severe COVID-19", "technology development", "thrombotic", "thrombotic complications", "venous thromboembolism" ], "approved": true } }, { "type": "Grant", "id": "12026", "attributes": { "award_id": "5R01AI165808-02", "title": "Lipid Bilayer Remodeling and Protein Intermediates During Membrane Fusion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24689, "first_name": "Uday K.", "last_name": "Shankar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-25", "end_date": "2026-06-30", "award_amount": 589522, "principal_investigator": { "id": 25546, "first_name": "Kelly Keisen", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Protein-mediated membrane fusion is essential for a multitude of fundamental biological processes. Despite intensive study, at present we have a limited mechanistic understanding of how fusion protein machinery manipulates lipid membranes in order to induce their fusion. This lack of knowledge is particularly acute regarding the structure of membrane intermediates, the extent to which their leaflets are bent or disrupted into nonbilayer structures, and how they are coordinated and remodeled by fusogens. Similarly, in terms of the structure of the fusion proteins themselves, very little structural information is available to describe how they change as they drive membrane fusion. These are processes that are targeted by therapeutics such as fusion inhibitors or neutralizing antibodies in the case of preventing virus infection, and they are processes that can go awry as a result of disease mutations for cellular fusogens. The proposed studies will expand our understanding of these fundamental processes and reveal general principles employed by divergent fusion machines. Cryo-electron microscopy and structural mass spectrometry provide powerful complementary methods to directly image and probe membrane fusion because they allow us to trigger a fusion reaction under native conditions then trap and then image or analyze intermediate states over the course of the reaction. Cryo-electron tomography in particular can resolve individual fusion machines and membrane leaflets captured in the process of fusing and can discern when the proteins and membranes have adopted non-canonical intermediate structures. Hydrogen/deuterium- exchange mass spectrometry complements cryo-EM by enabling us to monitor local backbone dynamics under native conditions. This approach is particularly effective for tracking conformational changes and for comparing protein structure in different states. Building on our work with influenza virus, we will apply these methods to investigate pathways of membrane fusion in two Class I viral fusion systems: the Env fusion protein used by HIV and the S spike protein used by SARS-CoV-2. These fusion machines employ sequential modes of activation and triggering involving receptor priming followed by either coreceptor binding (Env) or a proteolytic cleavage event (S). These systems thus offer the opportunity to analyze in detail the fusion system arrested at an intermediate, primed stage. For each of these systems, our goal is to image the architecture and progression of membrane remodeling leading to formation of fusion pores and to understand the means by which the protein machinery induces two separate membrane bilayers to join into one. By performing such an analysis, we will gain novel insight into general, obligatory events in Class I protein-mediated membrane fusion, while also revealing system-specific mechanisms. Our study should thus advance our structural and mechanistic understanding of the fundamental process of biological membrane fusion while also providing valuable insight into the mechanism of host invasion by two viruses that have ignited major pandemics impacting global health and society.", "keywords": [ "2019-nCoV", "ACE2", "Acute", "Address", "Adopted", "Alphavirus", "Architecture", "Binding", "Biological", "Biological Process", "CD4 Antigens", "Cell fusion", "Cells", "Chikungunya virus", "Chimeric Proteins", "Complement", "Coronavirus", "Coupled", "Cryo-electron tomography", "Cryoelectron Microscopy", "Deuterium", "Development", "Disease", "Engineering", "Event", "Evolution", "Fertilization", "Freezing", "Germ Cells", "Goals", "HIV", "Hydrogen", "Image", "Individual", "Influenza Hemagglutinin", "Invaded", "Investigation", "Knowledge", "Length", "Lipid Bilayers", "Maintenance", "Mass Spectrum Analysis", "Mediating", "Membrane", "Membrane Fusion", "Membrane Lipids", "Membrane Proteins", "Methods", "Mitochondria", "Molecular", "Molecular Conformation", "Monitor", "Mutation", "Pathway interactions", "Peptide Hydrolases", "Physical Function", "Placenta", "Process", "Proteins", "Reaction", "Research", "Resolution", "Sampling", "Signal Transduction", "Societies", "Structure", "Synapses", "Synaptic Vesicles", "System", "TMPRSS2 gene", "Testing", "Time", "Tissues", "Vertebral column", "Vesicle", "Viral", "Virion", "Virus", "Virus Diseases", "Virus-like particle", "Visualization", "Work", "density", "dimer", "experimental study", "global health", "influenzavirus", "inhibitor", "insight", "molecular imaging", "nanometer resolution", "neutralizing antibody", "novel", "pandemic impact", "prevent", "programs", "protein structure", "receptor", "receptor binding", "targeted treatment", "trafficking" ], "approved": true } }, { "type": "Grant", "id": "12027", "attributes": { "award_id": "5R21AI170171-02", "title": "Curating a Knowledge Base for Individuals with Coinfection of HIV and SARS-CoV-2: EHR-based Data Mining", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6828, "first_name": "Rosemary G", "last_name": "McKaig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-13", "end_date": "2024-06-30", "award_amount": 185676, "principal_investigator": { "id": 4919, "first_name": "Xiaoming", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has cast a heavy burden on individuals with HIV infection. Based on data of 15,522 hospitalized patients with the coinfection of HIV and SARS-CoV-2 from 24 countries, a recent World Health Organization (WHO) report for the first time confirmed that HIV to be an independent risk factor for severe COVID-19. Despite a generally high risk of severe COVID-19 clinical course in individuals with HIV, the interactions between SARS-CoV-2 and HIV infections remain unclear. For example, the severity of COVID-19 in individuals with HIV is correlated with certain comorbidities in which some of these comorbidities are more prevalent in patients with HIV than other populations. Yet, several contradictory findings suggested the predominant role of comorbidities in the severity of COVID-19 regardless of HIV infection. Individuals with low CD4+ T-cell count (e.g., <200~500 cells/µL) and unsuppressed viral load are associated with severe clinical course, yet the role of antiretroviral therapy (ART) exposure and adherence in the context of COVID-19 exposure needs to be examined. Risk factors for the severe clinical course of the coinfection are undetermined because individuals with the same or similar severity level of COVID-19 show different clinical characteristics. To fill address these knowledge gaps, this study will establish an EHR-based cohort for individuals with HIV/SARS- CoV-2 coinfection and develop large-scale EHR-based data mining to examine the interactions between HIV and SARS-CoV-2 infections and systematically identify and validate factors contributing to the severe clinical course of the coinfection. Ultimately, collected clinical evidence will be implemented and used to pilot test a Clinical Decision Support (CDS) prototype to assist providers in screening and referral of at-risk patients in real-world clinics.", "keywords": [ "2019-nCoV", "Acquired Immunodeficiency Syndrome", "Acute", "Address", "Adherence", "CD4 Lymphocyte Count", "CD4 Positive T Lymphocytes", "COVID-19", "COVID-19 pandemic", "COVID-19 risk", "COVID-19 severity", "COVID-19 vaccination", "Cardiovascular Diseases", "Cell Count", "Cells", "Characteristics", "Chronic Kidney Failure", "Chronic Obstructive Pulmonary Disease", "Clinic", "Clinical", "Clinical Data", "Clinical Trials", "Clinical Trials Design", "Collaborations", "Consultations", "Country", "Data", "Dependence", "Development", "Diagnosis", "Disparity", "Electronic Health Record", "Etiology", "Event", "Goals", "HIV", "HIV Infections", "Health", "Hospitalization", "Human immunodeficiency virus test", "Immune", "Individual", "Inflammatory", "Intervention", "Knowledge", "Laboratories", "Malignant Neoplasms", "Measures", "Methodology", "Modeling", "Natural History", "Non-Insulin-Dependent Diabetes Mellitus", "Obesity", "Ontology", "Outcome", "Pathway interactions", "Patients", "Pattern", "Pharmaceutical Preparations", "Phase", "Phenotype", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Procedures", "Prognosis", "Provider", "Public Health", "Reporting", "Risk", "Risk Factors", "Role", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "Sampling", "Series", "Services", "Severe Acute Respiratory Syndrome", "Severities", "Social Behavior", "Structure", "System", "Therapeutic", "Time", "Training", "Viral", "Viral Load result", "Visit", "Work", "World Health Organization", "antiretroviral therapy", "biomedical ontology", "clinical decision support", "clinically actionable", "co-infection", "cohort", "comorbidity", "coronavirus disease", "data integration", "data mining", "demographics", "design", "disease prognosis", "evidence base", "high risk", "knowledge base", "machine learning model", "outreach", "patient screening", "pilot test", "pre-exposure prophylaxis", "prisma", "prospective", "prototype", "screening", "severe COVID-19", "social health determinants", "substance use", "therapy adherence", "trait", "usability" ], "approved": true } }, { "type": "Grant", "id": "12028", "attributes": { "award_id": "5R01AI167272-02", "title": "Clinical analysis and therapeutic development of exosomal ACE2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6115, "first_name": "DIPANWITA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-15", "end_date": "2027-06-30", "award_amount": 748517, "principal_investigator": { "id": 25551, "first_name": "Deyu", "last_name": "Fang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25552, "first_name": "Huiping", "last_name": "Liu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 924, "ror": "", "name": "NORTHWESTERN UNIVERSITY AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Biomarker-guided treatment is key to improve outcomes of many diseases. The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global crisis due to lagged vaccination and inefficient control of the virus, which has caused over 253 million cases and more than 5.1 million deaths as of November 15, 2021. For potential new strains that may infect vulnerable populations or escape from vaccination-mediated prevention, biomarker-guided specific therapeutics against broad strains of SARS- CoV-2 as well as future corona viruses are still urgently required to prevent viral spreading and save human lives from severe COVID-19. In exploration of soluble components in the plasma of COVID-19 patients during acute infection and convalescent phase, we detected ACE2 expression in a subset of circulating exosomes and found that the levels of ACE2+ exosomes (exoACE2) are associated with severity of COVID-19. Purified ACE2+ exosomes competitively blocked the SARS-CoV-2 infection through inhibiting the viral Spike protein with its cellular receptor ACE2. We hypothesize that the exosomal ACE2 not only serves a biomarker for COVID-19 pathogenesis but also represents an innovative decoy therapy to treat all strains of coronaviruses that use ACE2 for viral entry. We propose two specific aims: (1) to establish a standard clinical assay for exoACE2 analysis; and (2) to develop exoACE2 therapeutics against the current and future broad strains of coronaviruses. Two academic institutions (Northwestern University and MD Anderson Cancer Center) will team up with the industry partner ExoMira Medicine for collaborative translation of exoACE2 into clinical applications, i.e. biomarker-guided therapy against SARS-CoV-2 and other coronaviruses.", "keywords": [ "2019-nCoV", "ACE2", "Acceleration", "Angiotensin Receptor", "Antibodies", "Antibody Specificity", "Antiviral Response", "Binding", "Biological Assay", "Biological Markers", "Blood", "CD81 gene", "COVID-19", "COVID-19 pandemic", "COVID-19 pathogenesis", "COVID-19 patient", "COVID-19 severity", "COVID-19 therapeutics", "COVID-19 treatment", "Cancer Center", "Cells", "Cessation of life", "Clinical", "Clinical Trials", "Communication", "Coronavirus", "Detection", "Devices", "Diagnosis", "Diameter", "Disease", "Epithelial", "Epitopes", "Future", "Health", "Hospitalization", "Human", "Infection", "Institution", "Kidney", "Mediating", "Medicine", "Membrane Lipids", "Membrane Proteins", "Molecular", "Multivesicular Body", "Nature", "Nucleic Acids", "Outcome", "Patients", "Persons", "Phase", "Plasma", "Pre-Clinical Model", "Prevention", "Production", "Proteins", "Protocols documentation", "Public Health", "Recombinants", "Research Personnel", "SARS coronavirus", "SARS-CoV-2 infection", "SARS-CoV-2 inhibitor", "Stains", "TSG101 gene", "Technology", "Therapeutic", "Translating", "Translations", "Universities", "Vaccinated", "Vaccination", "Validation", "Variant", "Viral", "Virus", "Virus Replication", "Vulnerable Populations", "acute infection", "clinical application", "clinical biomarkers", "commercialization", "convalescent plasma", "deep learning algorithm", "exosome", "extracellular vesicles", "improved outcome", "industry partner", "innovation", "intercellular communication", "manufacture", "microvesicles", "neutralizing antibody", "novel", "novel therapeutics", "pandemic disease", "pneumocyte", "preclinical study", "preclinical trial", "prevent", "receptor", "receptor binding", "response", "scale up", "severe COVID-19", "targeted treatment", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "12029", "attributes": { "award_id": "5R01AI171426-02", "title": "Study of arenavirus assembly", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7012, "first_name": "LESLEY CONRAD", "last_name": "Dupuy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-20", "end_date": "2027-06-30", "award_amount": 540203, "principal_investigator": { "id": 25553, "first_name": "MING", "last_name": "LUO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25554, "first_name": "Z Hong", "last_name": "ZHOU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 964, "ror": "https://ror.org/03qt6ba18", "name": "Georgia State University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The devastating impact on public health, global economy and social stability incurred by the COVID-19 pandemic in the last two years has highlighted the importance of basic research into zoonotic pathogens. This application describes structural and functional studies into the rodent-borne human pathogen lymphocytic choriomeningitis virus (LCMV), a member of the Arenaviridae family in the Bunyavirales order. Like other members of the same family, LCMV has a negative sense, bi-segmented genome consisting of a large (L) and a small (S) segment. The L segment encodes the RNA-dependent RNA polymerase (L RdRp) protein and the multi-functional matrix protein (Z). The S segment encodes the viral nucleoprotein (NP) and the glycoprotein (GP) precursor of the glycoprotein complex (GPC) that is later cleaved into a stable signal peptide (SSP), GP1, and GP2. In the virion, nucleocapsids of NP coated L and S segments associated with the L protein are copackaged through interactions with membrane-associated Z proteins, which also interact with GPs embedded in the membrane envelope. Although structures of individual proteins from AVs have been solved by x-ray crystallography or cryo electron microscopy (cryoEM), the architectural organization of these proteins in the virion and the assembly mechanism of NP and RNA into the nucleocapsid are poorly understood. We hypothesize that NP interacts with genomic RNA segments and L RdRp to form a nucleocapsid, which is recruited to GP-decorated membrane patches through Z for budding of virions. The proposed structural and functional studies aim to test this hypothesis of LCMV virion and nucleocapsid assembly with techniques just established by our team in the collaborative studies of vesicular stomatitis virus (VSV), another negative sense RNA virus. Specifically, cryo electron tomography (cryoET) will be used to reconstruct the first 3D model of the LCMV virion at molecular resolution and atomic models of individual proteins will be fitted into the virion tomogram to establish the architectural framework of the virion and to unveil molecular interactions among GP, Z, NP and L proteins (Aim 1). Near-atomic resolution with novel sub-particle reconstruction method will be used to image fully assembled nucleocapsids consisting of NP protein and genomic RNA segment to define the protein-RNA interactions at atomic details. The nucleocapsid structure will be used to guide sub-particle reconstruction workflow and be complemented by in situ structures of nucleocapsids from virions (Aim 2). In both Aims, structure-guided functional studies will be performed to test hypotheses of assembly mechanisms of LCMV nucleocapsid and virion. Structure-function relationship relevant to viral RNA synthesis will also be explored. Overall, the anticipated results will provide new insights into the mechanism of virion assembly and viral RNA synthesis, not only for LCMV but also for Arenaviruses in general. The proposed studies harness cutting-edge technologies in structural biology and will generate new knowledge of viral structures currently unavailable to any of Arenaviruses. As such, the innovative studies shall make unique contributions by accelerating discoveries of antiviral agents and vaccines to control future AV outbreaks.", "keywords": [ "Acceleration", "Animals", "Antiviral Agents", "Architecture", "Arenavirus", "Basic Science", "Binding", "Binding Proteins", "Bunyavirales", "COVID-19 pandemic", "Cell membrane", "Cells", "Collaborations", "Complement", "Complex", "Cryo-electron tomography", "Cryoelectron Microscopy", "Data", "Density Gradient Centrifugation", "Deposition", "Disease Outbreaks", "Family", "Future", "GP2 gene", "GTPBP1 gene", "Genetic Transcription", "Genome", "Genomic Segment", "Glycoproteins", "Human", "Image", "In Situ", "Individual", "Joints", "Junin virus", "Knowledge", "Lassa virus", "Lymphocyte Function", "Lymphocytic choriomeningitis virus", "Measures", "Membrane", "Messenger RNA", "Methods", "Modeling", "Molecular", "Mutation", "Nucleocapsid", "Nucleoproteins", "Old World Arenaviruses", "Peptide Signal Sequences", "Pichinde virus", "Polymerase", "Proteins", "Public Health", "RNA", "RNA Sequences", "RNA Viruses", "RNA chemical synthesis", "RNA-Directed RNA Polymerase", "RNA-Protein Interaction", "Resolution", "Rodent", "Series", "Signal Transduction", "Structure", "Structure-Activity Relationship", "System", "Techniques", "Technology", "Testing", "Tomogram", "Ultracentrifugation", "Vaccines", "Vesicular stomatitis Indiana virus", "Viral", "Viral Hemorrhagic Fevers", "Viral Proteins", "Virion", "Virus", "Virus Assembly", "X-Ray Crystallography", "Zoonoses", "density", "design", "experimental study", "future pandemic", "genomic RNA", "human pathogen", "image reconstruction", "innovation", "insight", "member", "novel", "novel strategies", "pathogen", "plasma protein Z", "prototype", "recombinant virus", "reconstruction", "recruit", "social", "structural biology", "three dimensional structure", "three-dimensional modeling", "vaccine development", "viral RNA" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1405, "count": 14046 } } }